WO2012044090A3 - 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 - Google Patents

단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 Download PDF

Info

Publication number
WO2012044090A3
WO2012044090A3 PCT/KR2011/007194 KR2011007194W WO2012044090A3 WO 2012044090 A3 WO2012044090 A3 WO 2012044090A3 KR 2011007194 W KR2011007194 W KR 2011007194W WO 2012044090 A3 WO2012044090 A3 WO 2012044090A3
Authority
WO
WIPO (PCT)
Prior art keywords
compound
protein
novel
inhibiting action
kinase
Prior art date
Application number
PCT/KR2011/007194
Other languages
English (en)
French (fr)
Other versions
WO2012044090A2 (ko
Inventor
정원근
나정은
임춘영
박철홍
조중명
노성구
이휘성
최종류
Original Assignee
크리스탈지노믹스(주)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 크리스탈지노믹스(주) filed Critical 크리스탈지노믹스(주)
Priority to KR1020137010975A priority Critical patent/KR20130141500A/ko
Publication of WO2012044090A2 publication Critical patent/WO2012044090A2/ko
Publication of WO2012044090A3 publication Critical patent/WO2012044090A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

본 발명은 단백질 키나제(protein kinase)에 대해 우수한 억제 효과를 갖는 신규한 아미노퀴나졸린 화합물; 상기 화합물의 단백질 키나제에 의해 유도된 비정상적인 세포 반응과 관련된 질환의 예방 또는 치료용 용도; 상기 화합물을 포함하는 약학 조성물; 및 상기 화합물을 이용한 치료방법에 관한 것으로, 본원 발명의 화합물은 단백질 키나제에 의해 유도된 비정상적인 세포 반응과 관련된 질환의 예방 또는 치료에 유용하게 사용될 수 있다.
PCT/KR2011/007194 2010-09-29 2011-09-29 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 WO2012044090A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020137010975A KR20130141500A (ko) 2010-09-29 2011-09-29 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38776510P 2010-09-29 2010-09-29
US61/387,765 2010-09-29

Publications (2)

Publication Number Publication Date
WO2012044090A2 WO2012044090A2 (ko) 2012-04-05
WO2012044090A3 true WO2012044090A3 (ko) 2012-06-21

Family

ID=45893669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/007194 WO2012044090A2 (ko) 2010-09-29 2011-09-29 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물

Country Status (2)

Country Link
KR (1) KR20130141500A (ko)
WO (1) WO2012044090A2 (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968318A4 (en) * 2013-03-15 2016-12-14 Shifa Biomedical Corp ANTI-PCSK9 COMPOUNDS AND METHODS FOR TREATING AND / OR PREVENTING CARDIOVASCULAR DISEASES
TWI641592B (zh) 2013-04-02 2018-11-21 英商瑞斯比維特有限公司 激酶抑制劑
AR096654A1 (es) * 2013-06-20 2016-01-27 Ab Science Derivados de benzimidazol como inhibidores selectivos de proteína quinasa
KR102338568B1 (ko) 2013-12-06 2021-12-13 엠와이씨헌터 테라퓨틱스, 아이엔씨. 퀴나졸린 유도체
GB201401086D0 (en) * 2014-01-23 2014-03-12 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201401806D0 (en) * 2014-02-03 2014-03-19 Orthogenics As Novel methods for diagnosis and therapy
WO2015143652A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
AU2015341913B2 (en) * 2014-11-03 2020-07-16 Iomet Pharma Ltd Pharmaceutical compound
US9701677B2 (en) 2014-12-24 2017-07-11 Gilead Sciences, Inc. Fused pyrimidine compounds
AU2015371257B2 (en) 2014-12-24 2018-09-06 Gilead Sciences, Inc. Isoquinoline compounds for the treatment of HIV
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
ES2903283T3 (es) 2016-08-31 2022-03-31 Jiangsu Hengrui Medicine Co Derivado de oxipicolinamida, método de preparación y uso farmacéutico del mismo
CN106518790B (zh) * 2016-11-02 2019-01-15 河南省商业科学研究所有限责任公司 一种2,4-二氯喹唑啉的合成方法
EP4211119A1 (en) * 2020-09-02 2023-07-19 Merck Sharp & Dohme LLC 2-aminoquinazolines as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009084695A1 (ja) * 2007-12-28 2009-07-09 Carna Biosciences Inc. ２－アミノキナゾリン誘導体
US20100048561A1 (en) * 2006-04-06 2010-02-25 Novartis Vaccines & Diagnostics, Inc. Quinazolines for pdk1 inhibition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048561A1 (en) * 2006-04-06 2010-02-25 Novartis Vaccines & Diagnostics, Inc. Quinazolines for pdk1 inhibition
WO2009084695A1 (ja) * 2007-12-28 2009-07-09 Carna Biosciences Inc. ２－アミノキナゾリン誘導体

Also Published As

Publication number Publication date
KR20130141500A (ko) 2013-12-26
WO2012044090A2 (ko) 2012-04-05

Similar Documents

Publication Publication Date Title
WO2012044090A3 (ko) 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2012142498A3 (en) Mif inhibitors and their uses
TR201901114T4 (tr) Özgün immünomodülatör ve anti inflamatuvar bileşikler.
IN2012DN00624A (ko)
EA201201648A1 (ru) Стимуляторы sgc
WO2014031928A3 (en) Heterocyclic modulators of hif activity for treatment of disease
WO2014067986A8 (en) Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
WO2012045089A3 (en) Methods for the treatment of allergic diseases
WO2011113013A3 (en) Methods and compositions for treating viral or virally-induced conditions
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
BR112014000380A2 (pt) composição farmacêutica, métodos para tratamento e usos dos mesmos
WO2012038504A3 (en) Breast cancer therapeutics
NZ727304A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
EP2418945A4 (en) Mineral salt-sulfuric acid compositions and methods for their use
WO2011091366A3 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
WO2014031933A3 (en) Heterocyclic modulators of hif activity for treatment of disease
WO2012170807A3 (en) Anti-pseudomonas psl binding molecules and uses thereof
WO2014031936A3 (en) Heterocyclic modulators of hif activity for treatment of disease
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
BR112013028420A2 (pt) tratamento de mieloma múltiplo
GB2497453B8 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
IN2014DN08385A (ko)
UA111520C2 (uk) [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11829596

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20137010975

Country of ref document: KR

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 11829596

Country of ref document: EP

Kind code of ref document: A2